European Union antitrust regulators on Tuesday said a full-blown probe has been opened into France’s financial support of beleaguered nuclear group Areva SA’s restructuring plans to ensure the government didn’t give it an unfair advantage.
The European Commission said France notified it of the group’s restructuring plans in April, which includes state aid of around €4 billion ($4.42 billion) in the form of a public capital injection into Areva.
“Given the size and importance of the restructuring of Areva, the commission has to carefully assess that the restructuring plan is sound… Our aim is to ensure a sustainable future for Areva without the need for further government support,” said EU competition chief Margrethe Vestager.
The EU said it was examining whether Areva’s restructuring plans are realistic enough to ensure the company can operate without “constant injections of public funds.” The commission said it also wants to ensure the group sufficiently contributes to the restructuring costs and that France is taking appropriate steps to limit any distortions to competition.
The opening of an investigation isn’t a surprise for the French government, an Economy Ministry official said Tuesday.
“The minister and the commissioner had several meetings since the project was notified in April,” he said. “The investigation is pretty standard procedure. The commission will verify our project respects the EU rules governing state aid and we are confident our project is solid and the outcome will be positive.”
Full Content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas